Cargando…

Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients

Catheter-related bloodstream infections (CRBSI) are major complications for patients with life-threatening conditions requiring chronic vascular catheterization. The wide range of etiologic microbes and the ongoing development of resistance to antimicrobials with specific mechanisms of action make t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reidenberg, Bruce E., Wanner, Christoph, Polsky, Bruce, Castanheira, Mariana, Shelip, Alla, Stalleicken, Dirk, Pfaffle, Antony E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978892/ https://www.ncbi.nlm.nih.gov/pubmed/29214504 http://dx.doi.org/10.1007/s10096-017-3157-7

Ejemplares similares

2117. In Vitro Antimicrobial Activity of Taurolidine against Candida auris Bloodstream Isolates from Global Sources
por: Pfaffle, Anthony, et al.
Publicado: (2023)

Taurolidine Lock Is Superior to Heparin Lock in the Prevention of Catheter Related Bloodstream Infections and Occlusions
por: Olthof, Evelyn D., et al.
Publicado: (2014)

Is Taurolidine-citrate an effective and cost-effective hemodialysis catheter lock solution? A systematic review and cost- effectiveness analysis
por: Kavosi, Zahra, et al.
Publicado: (2016)

The best solution down the line: an observational study on taurolidine- versus citrate-based lock solutions for central venous catheters in hemodialysis patients
por: van Roeden, Sonja, et al.
Publicado: (2021)

Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients
por: Simon, Arne, et al.
Publicado: (2008)

CATERPILLAR-study protocol: an assessor-blinded randomised controlled trial comparing taurolidine-citrate-heparin to heparin-only lock solutions for the prevention of central line-associated bloodstream infections in paediatric oncology patients
por: van den Bosch, Ceder Hildegard, et al.
Publicado: (2023)

Taurolidine Peritoneal Dialysis Catheter Lock to Treat Relapsing Peritoneal Dialysis Peritonitis
por: Alvarez Nadal, Marta, et al.
Publicado: (2020)

Taurolidine lock solution for catheter-related bloodstream infections in pediatric patients: A meta-analysis
por: Sun, Yan, et al.
Publicado: (2020)

Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT)
por: Gudiol, C., et al.
Publicado: (2018)

Trisodium citrate 4% versus heparin as a catheter lock for non-tunneled hemodialysis catheters in critically ill patients: a multicenter, randomized clinical trial
por: Quenot, Jean-Pierre, et al.
Publicado: (2019)

Reducing catheter-associated complications using 4% sodium citrate versus sodium heparin as a catheter lock solution
por: Huang, He-ming, et al.
Publicado: (2019)

Benefits and harms of citrate locking solutions for hemodialysis catheters: a systematic review and meta-analysis
por: Grudzinski, Alexa, et al.
Publicado: (2015)

2110. Taurolidine-Citrate Lock Solution for the Prevention of Central-Line-associated Bloodstream Infection (CLABSI) in Pediatric Hematology-Oncology and Gastrointestinal Failure Patients with High Baseline CLABSI Rates
por: Chong, Chia Yin, et al.
Publicado: (2018)

Taurolidine Lock Solutions for the Prevention of Catheter-Related Bloodstream Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Liu, Yong, et al.
Publicado: (2013)

Prevention of tunneled cuffed catheter dysfunction with prophylactic use of a taurolidine urokinase lock: A randomized double-blind trial
por: Bonkain, Florence, et al.
Publicado: (2021)

Randomised clinical trial: 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition
por: Wouters, Y., et al.
Publicado: (2018)

A New Method for the Measurement of International Normalized Ratio in Hemodialysis Patients with Heparin-Locked Tunneled Dialysis Catheters
por: Seghers, Céline B., et al.
Publicado: (2020)

Taurolidine cooperates with antineoplastic drugs in neuroblastoma cells
por: Eschenburg, Georg, et al.
Publicado: (2014)

Abstract: Suture Materials Containing the Antimicrobial Taurolidine
por: Lorenc, Z. Paul, et al.
Publicado: (2016)

Citrate Anticoagulation for CRRT in Children: Comparison with Heparin
por: Fernández, Sara Nicole, et al.
Publicado: (2014)

Comparison of heparin to citrate as a catheter locking solution for non-tunneled central venous hemodialysis catheters in patients requiring renal replacement therapy for acute renal failure (VERROU-REA study): study protocol for a randomized controlled trial
por: Bruyère, Rémi, et al.
Publicado: (2014)

Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database
por: Giuliano, F, et al.
Publicado: (2010)

Clinical application of 4% sodium citrate and heparin in the locking of central venous catheters (excluding dialysis catheters) in intensive care unit patients: A pragmatic randomized controlled trial
por: Deng, Yuchun, et al.
Publicado: (2023)

Pharmacokinetic study and evaluation of the safety of taurolidine for dogs with osteosarcoma
por: Marley, Kevin, et al.
Publicado: (2013)

Efficacy of Taurolidine Irrigation in Primary Total Knee Arthroplasty
por: Woo, Young Ha, et al.
Publicado: (2018)

Short-term treatment with taurolidine is associated with liver injury
por: Fahrner, René, et al.
Publicado: (2017)

Pseudohypernatremia secondary to trisodium citrate (Citra-Lock(TM))
por: Milliere, Janice, et al.
Publicado: (2016)

Comparison between regional citrate anticoagulation and heparin for intermittent hemodialysis in ICU patients: a propensity score-matched cohort study
por: Leroy, Christophe, et al.
Publicado: (2021)

Re-Evaluating the Protective Effect of Hemodialysis Catheter Locking Solutions in Hemodialysis Patients
por: Chen, Chang-Hua, et al.
Publicado: (2019)

TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma
por: Daigeler, Adrien, et al.
Publicado: (2008)

2117. Catheter-related Bacteremia in Hemodialysis Patients on Antibiotic Lock Therapy: Are Antibiotic Locks Ineffective?
por: Krishna, Amar, et al.
Publicado: (2018)

Regional Citrate Anticoagulation for Intermittent Hemodialysis in Dogs
por: Francey, T., et al.
Publicado: (2017)

The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro
por: Marley, Kevin, et al.
Publicado: (2013)

Eradication of Ventricular Assist Device Driveline Infection in Paediatric Patients with Taurolidine
por: Weichsel, Johannes, et al.
Publicado: (2022)

Antifungal activity of Taurolidine against Mucorales: An in vitro study on clinical isolates
por: Jafarian, Hadis, et al.
Publicado: (2022)

Locked Away—Prophylaxis and Management of Catheter Related Thrombosis in Hemodialysis
por: Szymańska, Joanna, et al.
Publicado: (2021)

Systematic review of locking solutions for non‐tunneled hemodialysis catheters
por: Boucley, Isabelle, et al.
Publicado: (2022)

Meta‐analysis of the efficacy of taurolidine in reducing catheter‐related bloodstream infections for patients receiving parenteral nutrition
por: Vernon‐Roberts, Angharad, et al.
Publicado: (2022)

Recurrent early filter clotting in regional citrate anticoagulated continuous venovenous hemodialysis due to undetected antibodies to heparin-platelet factor 4 complexes
por: Slowinski, T, et al.
Publicado: (2010)

Clinical review: Anticoagulation for continuous renal replacement therapy - heparin or citrate?
por: Oudemans-van Straaten, Heleen M, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_14ror3fccaelifanf6jedkma05